Perlegen Sciences Appoints Robert Middlebrook to Head Corporate Development
November 19 2003 - 7:00AM
PR Newswire (US)
Perlegen Sciences Appoints Robert Middlebrook to Head Corporate
Development MOUNTAIN VIEW, Calif., Nov. 19 /PRNewswire/ -- Perlegen
Sciences, Inc., a privately held genetics company, today announced
that Robert Middlebrook has joined Perlegen in the newly created
role of Chief Corporate Development Officer. "Perlegen is expanding
its roster of world class corporate, government and academic
partners and simultaneously moving rapidly toward the in-licensing
of late-stage drug candidates," said Brad Margus, Chief Executive
Officer of Perlegen. "As a general manager, Rob has helped lead a
number of organizations through significant change, while as an
investment professional, he has managed billions of dollars of
institutional capital. With this rare blend of skills, Rob will
help Perlegen accelerate its migration from development to
production in specific therapeutic areas by positioning us most
effectively in the capital markets and in the competitive markets
within which we operate." Mr. Middlebrook joins Perlegen following
an eleven year tenure with Fidelity Investments where he held a
number of key leadership positions in the firm's money management
operation, including Chief Investment Officer of the Managed Income
Group and Head Trader of the Municipal Money Market Group. More
recently, in the role of Senior Vice President, Mr. Middlebrook
lead reengineering efforts in the firm's supply management
operation, overseeing the company's multi-billion annual spend on
goods and services, and in Fidelity's HR and payroll outsourcing
practice. Prior to joining Fidelity, Mr. Middlebrook was Vice
President and Principal of Regent Capital Corporation where he was
responsible for structuring a broad range of investment
opportunities and corporate development transactions. He also spent
four years in sales management in the defense electronics industry
with Alpha Industries, now Skyworks Solutions. He earned a Master
of Business Administration degree from the Harvard Business School,
a Bachelor of Science degree in Business Management from Bucknell
University, and holds the Chartered Financial Analyst (CFA)
designation. "Perlegen has assembled an unparalleled array of
talent and technology that is swiftly moving pharmacogenomics from
a promise to a reality," said Mr. Middlebrook. "Perlegen is
intensely focused on accelerating, and bringing to a production
scale, its technology to help physicians and patients in their
quest for safe and effective medications. I am thrilled to help
execute this mission." About Perlegen Sciences Perlegen conducts
genetics research and develops products that impact and improve
people's lives through a proprietary, cost-effective method for
rapidly analyzing and comparing entire genomes. This whole genome
association study capability enables Perlegen to identify genes
that work in concert to cause common diseases and affect the body's
response to drugs. Perlegen is applying its genotyping capabilities
in ongoing pharmacogenomic and other research collaborations with
partners including: Bristol-Myers Squibb, Eli Lilly & Co.,
GlaxoSmithKline, Pfizer and Unilever. Formed in late 2000 as a
spin-off of Affymetrix, Inc. (NASDAQ:AFFX), Perlegen is
accelerating the development of therapeutics and diagnostics and
enabling a new paradigm of high-resolution whole genome scanning.
For more information about Perlegen and its technologies, visit
Perlegen's web site at http://www.perlegen.com/. Perlegen, the
Perlegen Logo and Perlegen Sciences are trademarks of Perlegen
Sciences, Inc. Contact: Perlegen Sciences, Inc. Brad Margus Chief
Executive Officer (650) 625-4500 DATASOURCE: Perlegen Sciences,
Inc. CONTACT: Brad Margus Chief Executive Officer of Perlegen
Sciences, Inc., +1-650-625-4500 Web site: http://www.perlegen.com/
Copyright
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Sep 2023 to Sep 2024